Publication Name	World Journal of Clinical Cases
Manuscript ID	90710
Country	Cyprus

Received	2023-12-11 20:53
Peer-Review Started	2023-12-11 20:53
To Make the First Decision
Return for Revision	2024-03-06 21:51
Revised	2024-03-19 04:20
Second Decision	2024-04-19 02:43
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-04-19 08:17
Articles in Press	2024-04-19 08:17
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2024-05-27 15:42
Publish the Manuscript Online	2024-05-29 12:34

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Editorial
Article Title	Antifungal pipeline: Is there light at the end of the tunnel?
Manuscript Source	Invited Manuscript
All Author List	Georgios Schinas, Nikolaos Spernovasilis and Karolina Akinosoglou
Funding Agency and Grant Number
Corresponding Author	Nikolaos Spernovasilis, BSc, MD, MSc, PhD, Director, Director, Department of Infectious Diseases, German Oncology Center, Limassol 4108, Cyprus. nikspe@hotmail.com
Key Words	Antifungals; Resistance; Fosmanogepix; Ibrexafungerp; Olorofim
Core Tip	The landscape of antifungal therapy has long been dominated by a handful of drug classes, namely azoles, polyenes, and echinocandins. Issues such as the development of resistance/tolerance, interactions and inherent toxicity, and a narrow spectrum of activity have limited their therapeutic utility to clinicians. All these limitations underline the urgent need for novel approaches, with the pipeline for new antifungals having been relatively dry for about 30 years. Thankfully, the pharmaceutical landscape has recently shown promising signs of innovation regarding antifungal agents.
Publish Date	2024-05-29 12:34
Citation	<p>Schinas G, Spernovasilis N, Akinosoglou K. Antifungal pipeline: Is there light at the end of the tunnel? <i>World J Clin Cases</i> 2024; 12(16): 2686-2691</p>
URL	https://www.wjgnet.com/2307-8960/full/v12/i16/2686.htm
DOI	https://dx.doi.org/10.12998/wjcc.v12.i16.2686

Full Article (PDF)	WJCC-12-2686-with-cover.pdf
Manuscript File	90710_Auto_Edited-YJP.docx
Answering Reviewers	90710-Answering reviewers.pdf
Audio Core Tip	90710-Audio core tip.mp3
Conflict-of-Interest Disclosure Form	90710-Conflict-of-interest statement.pdf
Copyright License Agreement	90710-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	90710-Language certificate.pdf
Peer-review Report	90710-Peer-review(s).pdf
Scientific Misconduct Check	90710-Bing-Zheng XM-2.png
Scientific Misconduct Check	90710-CrossCheck.png
Scientific Editor Work List	90710-Scientific editor work list.pdf
CrossCheck Report	90710-CrossCheck report.pdf